ERBA Mannheim Poised to Be Game Changer in Total Lab Automation at Medlab Middle East 2020

Food and Healthcare Press Releases Friday January 31, 2020 09:15
LONDON--31 Jan--PRNewswire/InfoQuest
  • 10 New launches at MEDLAB ME exhibition positions Erba as a complete end-to-end provider.
Erba Mannheim strengthens its portfolio of powerful and affordable solutions with a burst of new launches and a preview of their next generation NEXUS total lab automation system.

NEXUS total lab automation will offer powerful, modular solutions using advanced imaging and artificial intelligence. The NEXUS IA immunoassay analyzer uses unique magnetic CLIA bead technology and extensive panels to deliver a reliable and affordable solution, whilst the Nexus H Infinity Hematology analyzer uses computer vision to actually 'see' the sample and provides advanced diagnostics by counting, staining, imaging and analyzing 1000's of cells in less than a minute.

New Launches
  • Clinical Chemistry: New EC 90 electrolyte analyser with next generation thick film, maintenance-free electrodes in all-in-one sensor cartridge.
  • Diabetes: New HB715 automated desktop analyzer measuring glycated hemoglobin (HbA1c, HbA1ab, HbA1c, HbF, HbA0, HbA2/E/D, HbS, HbC) and designed for ease of use and low-cost operation.
  • Immunoassay: New ELAN 30s analyzer & New Rapid Tests– fully automated compact benchtop ELISA microstrip processor performing 6 different tests simultaneously, and Rapid Malaria and Dengue Tests with unique Dual Colour Detection system.
  • Hematology: New ESL 30 – fully automated ESR testing solution that improves result quality, laboratory safety and efficiency in mid-sized labs at an affordable price.
  • LIMS Software: a comprehensive middleware solution for integration of results from Erba and non-Erba instruments.
Alongside new products, updated versions of signature XL 200 and XL 640+ clinical chemistry analysers will be presented.

"At MEDLAB ME, we continue to demonstrate our commitment to becoming a leading player in the IVD market. With NEXUS we offer a unique entry level system for Total Lab Automation, enabling labs to scale their business with higher automation. Also, by significantly strengthening our product portfolio for small and medium sized labs and growing our global customer base, we are well placed to achieve our ambition." Romain Fournials, CCO.

Visit Erba Mannheim on booth Z4.B10, Hall 4 at MEDLAB ME 3-6 Feb 2020.
About Erba Mannheim

Erba Mannheim is a global company focused on delivering innovative, affordable and sustainable healthcare solutions. Operating and providing clinical diagnostic products in over 100 countries, Erba Mannheim utilizes a combination of cutting-edge European R&D with efficient low-cost manufacturing to produce innovative technologies, accessible to labs in all resource settings.

Contact: Arlene Hooper, Global Marketing Communications Manager, +44(0)7494208556, a.hooper@erbamannheim.com

Latest Press Release

Ansell Urges Global Priority For Supply Of Personal Protective Equipment

Ansell Limited, a global leader in protective solutions, is working with governments and health organizations worldwide to ensure unrestricted personal protective equipment (PPE) manufacture and supply is given top priority during the COVID-19...

Yiling Pharmacy Lianhua Qingwen has been approved by the Thai FDA

On March 31, Shijiazhuang Yiling Pharmaceutical Co., Ltd released a notice that they had received the approval of the modern herbal medicine registration issued by the Food and Drug Administration of Thailand. Lianhua Qingwen Capsule is recognized as in...

EW Nutrition Launches Industry-leading Webinar Series With Topical Antimicrobial Resistance Twin Sessions

Yesterday, German-based company EW Nutrition took a first step toward serving the animal production industry in these challenging times. The in-feed and on-farm solutions company has started a series of topical webinars on challenging issues such as...

Saxenda(R) Demonstrated Improvements in BMI and Body Weight in Adolescents With Obesity

Novo Nordisk today announced that the New England Journal of Medicine published results of a phase 3 trial evaluating the investigational use of Saxenda(R) (liraglutide 3.0 mg) in adolescents (aged 12–<18) with obesity.1 The study was accepted...

Johnson & Johnson Announces a Lead Vaccine Candidate for COVID-19; Landmark New Partnership with U.S. Department of Health & Human Services; and Commitment to Supply One Billion Vaccines Worldwide for Emergency Pandemic Use

Johnson & Johnson and BARDA Together Commit More than $1 Billion to Novel Coronavirus Vaccine Research and Development; Company Expects to Initiate Phase 1 Human Clinical Studies of Vaccine Candidate at Latest by September 2020 Johnson & Johnson...

Related Topics